



Amarin Corporation plc
Investor Relations Department
2 Pembroke House, Upper
Pembroke
Street 28-32
Dublin 2
Ireland

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: AMRN

Last Trade:	2.82
Trade Time:	4:00 PM ET Apr 23, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.76 - 4.60
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Apr 23, 2018

[Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer](#)

Apr 12, 2018

[Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions](#)

Apr 12, 2018

[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides](#)

Apr 4, 2018

[Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives](#)

Apr 4, 2018

[Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Feb 27, 2018

[Annual Report \(10-K\)](#)

Apr 20, 2018

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 2, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)